OccuLogix
Recent developments from OccuLogix outlined
Published in Healthcare Mergers, Acquisitions and Ventures Week, May 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at OccuLogix.
Report 1: OccuLogix, Inc. (OCCX) has obtained Investigational Device Exemption clearance from the U.S. Food and Drug Administration (FDA) to commence its pivotal (phase III) study of the RHEOTM procedure to treat the dry form of age-related macular degeneration.
The new study, called RHEO-AMD, is a multi-center, prospective, randomized (2:1), double-masked, sham-controlled trial designed to evaluate the safety and efficacy of the RHEOTM procedure in patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- AARP
AARP Launches Statewide Campaign for Health Care Reform - AARP Illinois
AARP Illinois Joins Governor in Fight for Health Care Reform - Abbott
Abbott Named Among the 'Top 10' on the Dave Thomas Foundation's '100 Best Adoption-Friendly Workplaces' List - Abbott
Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting - Abiomed, Inc.
Abiomed, Inc. Announces Partial Exercise of Over-Allotment Option in Public Offering - Absorption Systems
New Publications on Brain Penetration - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
